Cellular Immunotherapy Articles & Analysis
15 news found
Targeting these tumors with novel cellular immunotherapies will help address the unmet need for new treatment options for ovarian cancer patients. ...
We are very pleased to partner with Peter Mac’s Centre of Excellence in Cellular Immunotherapy, which was established in 2019 with backing from the Australian Federal Government and generous donors to the Peter MacCallum Cancer Foundation. ...
Details for the ASH 2022 presentation are as follows: Title: Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide (Haplo/Cy) By Infusion of Donor-Derived Expanded/Activated Gd T Cells: A Phase I Trial Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center Abstract #: 3323 Date and time: Sunday, December 11, 2022, 6:00 pm - 8:00 pm CDT Session: ...
” Oral Presentation Details: Abstract Title: Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML Session: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Relapsed/Refractory AMLS Session Date: Saturday, December ...
“We are proud to be partnering with the University of Louisville (UofL), the UofL Health - Brown Cancer Center and the Dunbar CAR T-Cell Program who have been at the forefront of clinical development and patient access to novel cellular immunotherapies. One of the biggest challenges facing cell therapy companies is efficient access to high-quality ...
Michael Schmitt, MD, MHBA is an internationally recognized expert in the field of cellular immunotherapy and is the author and co-author of more than 200 scientific publications. ...
ByArdigen
” About Umoja Biopharma Umoja Biopharma, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy. Umoja Biopharma, Inc. is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies by reprogramming immune cells in vivo to target and ...
(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the U.S. ...
Cellular Immunotherapies: Basic and Translational: Poster II Presentation date/time: Sunday, 12 December 2021; 6:00 pm Room: Georgia World Congress Center, Hall B5 Highlights: CYNK-101 is a cryopreserved, off the shelf, allogeneic NK cell product candidate, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 variant. The results ...
(NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today presented positive clinical data from the dose-escalation stage of its ongoing Phase 1 study of FT516 for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology Annual ...
The team at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop the µVS Delivery SystemTM for modified regulatory T cells. “Cellular immunotherapies using regulatory T cells (Tregs) show tremendous promise for the treatment of autoimmune ...
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and the University of California, San Francisco (UCSF) today announced they have formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies. Under the agreement, Thermo Fisher will build and operate a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing ...
” “Our Company made a strong debut last year as the first pre-revenue cellular immunotherapy firm to trade on the Hong Kong Stock Exchange,” added Dr. ...
About TVAX Biomedical TVAX Biomedical is a clinical stage development company advancing its targeted T cell-based immunotherapy for the treatment of cancer. The company’s proprietary therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. Unlike other forms of ...
Slawin, Founder and Managing Partner of Rapha Capital Management, previously founded Bellicum Pharmaceuticals, a NASDAQ-traded cellular immunotherapy company. 3DBio Therapeutics is advancing therapeutic-grade bioprinting to manufacture living tissues designed and created specifically for each individual patient. ...